CN118973580A - 包含sos1抑制剂和mek抑制剂的组合疗法 - Google Patents
包含sos1抑制剂和mek抑制剂的组合疗法 Download PDFInfo
- Publication number
- CN118973580A CN118973580A CN202380032771.6A CN202380032771A CN118973580A CN 118973580 A CN118973580 A CN 118973580A CN 202380032771 A CN202380032771 A CN 202380032771A CN 118973580 A CN118973580 A CN 118973580A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- sos1
- mek inhibitor
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329104P | 2022-04-08 | 2022-04-08 | |
| US63/329,104 | 2022-04-08 | ||
| PCT/US2023/017254 WO2023196218A2 (en) | 2022-04-08 | 2023-04-03 | Combination therapies comprising a sos1 inhibitor and a mek inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118973580A true CN118973580A (zh) | 2024-11-15 |
Family
ID=88243402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380032771.6A Pending CN118973580A (zh) | 2022-04-08 | 2023-04-03 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186453A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504197A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513802A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250002214A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118973580A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023250314A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3245730A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315648A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012446A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023196218A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250059182A1 (en) * | 2021-06-21 | 2025-02-20 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| JP4931419B2 (ja) | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| EP1838675A1 (en) | 2004-11-24 | 2007-10-03 | Laboratoires Serono S.A. | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US20060211073A1 (en) | 2005-03-21 | 2006-09-21 | May Earl W | Assay for B-Raf activity based on intrinsic MEK ATPase activity |
| TWI441637B (zh) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Mek雜環抑制劑及其使用方法 |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US20070172843A1 (en) | 2005-09-12 | 2007-07-26 | Conrad Susan E | MEK interacting protein 1 as diagnostic and therapeutic target for breast cancer treatment and prevention |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| WO2007071951A1 (en) | 2005-12-21 | 2007-06-28 | Astrazeneca Ab | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
| AU2007237901B2 (en) | 2006-04-18 | 2012-07-05 | Ardea Biosciences, Inc. | Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors |
| EA200802050A1 (ru) | 2006-04-19 | 2009-04-28 | Лаборатуар Сероно Са | Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов |
| WO2007123939A2 (en) | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
| GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| GB0625691D0 (en) | 2006-12-22 | 2007-01-31 | Astrazeneca Ab | Combination product |
| ES2547303T3 (es) | 2007-01-19 | 2015-10-05 | Ardea Biosciences, Inc. | Inhibidores de MEK |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| CA2694646C (en) | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| JP5615274B2 (ja) | 2008-07-01 | 2014-10-29 | ジェネンテック, インコーポレイテッド | Mekキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法 |
| CA2727250A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
| US8673919B2 (en) | 2009-03-27 | 2014-03-18 | Ardea Biosciences, Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors |
| CA2814617C (en) | 2009-10-13 | 2017-12-19 | Allostem Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| US20120238599A1 (en) | 2011-03-17 | 2012-09-20 | Chemizon, A Division Of Optomagic Co., Ltd. | Heterocyclic compounds as mek inhibitors |
| MA37405A1 (fr) | 2012-03-14 | 2016-03-31 | Lupin Ltd | Composés hétérocyclyle |
| CA3079071C (en) | 2012-10-19 | 2022-06-07 | Array Biopharma Inc. | Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same |
| US9556112B2 (en) | 2012-11-15 | 2017-01-31 | Duquesne University Of The Holy Ghost | Carboxylic acid ester prodrug inhibitors of MEK |
| WO2014204263A1 (en) | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| BR112017018580A2 (pt) | 2015-03-27 | 2018-04-24 | Jiangsu Hengrui Medicine Co., Ltd. | p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal |
| US10323035B2 (en) | 2015-04-01 | 2019-06-18 | Crystal Pharmatech Co., Ltd. | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof |
| US10350198B2 (en) | 2015-05-28 | 2019-07-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition of MEK inhibitor and preparation method thereof |
| HK1255102A1 (zh) | 2015-09-21 | 2019-08-02 | Plexxikon Inc. | 杂环化合物及其应用 |
| EP3558979B1 (en) * | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US20230101312A1 (en) | 2020-02-24 | 2023-03-30 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| AU2021263742A1 (en) * | 2020-04-27 | 2022-09-22 | Verastem, Inc. | Methods of treating abnormal cell growth |
| EP4188383A4 (en) | 2020-07-28 | 2025-01-08 | Mirati Therapeutics, Inc. | SOS1 INHIBITORS |
| WO2022051568A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| JP2024521788A (ja) * | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス, インコーポレイテッド | 併用療法 |
| CA3221608A1 (en) * | 2021-06-14 | 2022-12-22 | Kumquat Biosciences Inc. | Fused heteroaryl compounds useful as anticancer agents |
| US20250059182A1 (en) * | 2021-06-21 | 2025-02-20 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
-
2023
- 2023-04-03 CN CN202380032771.6A patent/CN118973580A/zh active Pending
- 2023-04-03 CA CA3245730A patent/CA3245730A1/en active Pending
- 2023-04-03 CA CA3255758A patent/CA3255758A1/en active Pending
- 2023-04-03 US US18/852,225 patent/US20250186453A1/en active Pending
- 2023-04-03 IL IL315648A patent/IL315648A/en unknown
- 2023-04-03 WO PCT/US2023/017254 patent/WO2023196218A2/en not_active Ceased
- 2023-04-03 KR KR1020247033661A patent/KR20250002214A/ko active Pending
- 2023-04-03 JP JP2024559468A patent/JP2025513802A/ja active Pending
- 2023-04-03 AU AU2023250314A patent/AU2023250314A1/en active Pending
- 2023-04-03 EP EP23785216.5A patent/EP4504197A4/en active Pending
-
2024
- 2024-10-07 MX MX2024012446A patent/MX2024012446A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4504197A4 (en) | 2026-03-18 |
| CA3255758A1 (en) | 2023-10-12 |
| US20250186453A1 (en) | 2025-06-12 |
| JP2025513802A (ja) | 2025-04-30 |
| WO2023196218A3 (en) | 2023-11-16 |
| EP4504197A2 (en) | 2025-02-12 |
| MX2024012446A (es) | 2024-11-08 |
| KR20250002214A (ko) | 2025-01-07 |
| WO2023196218A2 (en) | 2023-10-12 |
| CA3245730A1 (en) | 2023-10-12 |
| AU2023250314A1 (en) | 2024-10-03 |
| IL315648A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112955137B (zh) | 组合疗法 | |
| JP7546549B2 (ja) | 組み合わせ療法 | |
| JP2024537140A (ja) | Kras g12d阻害剤とsos1阻害剤との併用療法 | |
| US12280055B2 (en) | Combination therapies | |
| TWI620748B (zh) | 氨基噻唑化合物及其用途 | |
| JP2024537136A (ja) | KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法 | |
| JP2022500385A (ja) | 組み合わせ療法 | |
| JP2022500388A (ja) | 組み合わせ療法 | |
| CN119031916A (zh) | 包含sos1抑制剂和egfr抑制剂的组合疗法 | |
| JP2024537139A (ja) | KRAS G12D阻害剤とPI3Ka阻害剤との組み合わせ及び関連する治療方法 | |
| US20250177399A1 (en) | Combination therapies | |
| US20250186453A1 (en) | Combination therapies comprising a sos1 inhibitor and a mek inhibitor | |
| US11439625B2 (en) | Combination therapy for proliferative diseases | |
| EP3638690A1 (en) | Methods to treat gliomas using a stat3 inhibitor | |
| HK40101229A (zh) | 组合疗法 | |
| CN117615762A (zh) | 组合疗法 | |
| HK40109894A (en) | Combination therapies of kras g12d inhibitors with pan erbb family inhibitors | |
| HK40109896A (en) | Combination therapies of kras g12d inhibitors with shp-2 inhibitors | |
| HK40108895A (en) | Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment | |
| HK40109895A (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
| HK40055040A (en) | Combination therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |